| Dapagliflozin has been shown to be effective in controlling glycemic and non-glycemic parameters (weight and blood pressure) as add-on therapy in patients with type 2 DM in real-world clinical practice. | |
| Dapagliflozin can be considered as one of the important SGLT-2 inhibitors in patients with type 2 diabetes mellitus (DM) associated with obesity/high BMI or hypertension. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.